{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T13:01:53Z","timestamp":1787317313546,"version":"build-2736575974"},"reference-count":134,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1097\/mca.0000000000000408","type":"journal-article","created":{"date-parts":[[2016,7,14]],"date-time":"2016-07-14T11:13:18Z","timestamp":1468494798000},"page":"592-603","source":"Crossref","is-referenced-by-count":22,"title":["The role of HDL in plaque stabilization and regression"],"prefix":"10.1097","volume":"27","author":[{"given":"Jonathan E.","family":"Feig","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica L.","family":"Feig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George D.","family":"Dangas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-12-20210204","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1161\/01.ATV.14.2.177","article-title":"George Lyman Duff Memorial Lecture. Arterial imaging and atherosclerosis reversal","volume":"14","author":"Blankenhorn","year":"1994","journal-title":"Arterioscler Thromb"},{"key":"R2-12-20210204","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/S0033-0620(97)80041-2","article-title":"Regression of atherosclerosis: a review","volume":"39","author":"Schell","year":"1997","journal-title":"Prog Cardiovasc Dis"},{"key":"R3-12-20210204","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1161\/01.ATV.21.2.183","article-title":"Does therapeutic intervention achieve slowing of progression or bona fide regression of atherosclerotic lesions?","volume":"21","author":"Stein","year":"2001","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R4-12-20210204","first-page":"675","article-title":"Response to injury and atherogenesis","volume":"86","author":"Ross","year":"1977","journal-title":"Am J Pathol"},{"key":"R5-12-20210204","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/362801a0","article-title":"The pathogenesis of atherosclerosis: a perspective for the 1990s","volume":"362","author":"Ross","year":"1993","journal-title":"Nature"},{"key":"R6-12-20210204","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1152\/physrev.00047.2003","article-title":"Role of oxidative modifications in atherosclerosis","volume":"84","author":"Stocker","year":"2004","journal-title":"Physiol Rev"},{"key":"R7-12-20210204","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1073\/pnas.70.6.1753","article-title":"Evidence for a monoclonal origin of human atherosclerotic plaques","volume":"70","author":"Benditt","year":"1973","journal-title":"Proc Natl Acad Sci USA"},{"key":"R8-12-20210204","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/j.1749-6632.1976.tb43368.x","article-title":"Studies of regression of advanced atherosclerosis in experimental animals and man","volume":"275","author":"Wissler","year":"1976","journal-title":"Ann N Y Acad Sci"},{"key":"R9-12-20210204","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1001\/jama.1964.03060320157049","article-title":"Coronary thrombosis linked to fissure in atherosclerotic vessel wall","volume":"188","author":"Constantinides","year":"1964","journal-title":"JAMA"},{"key":"R10-12-20210204","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1136\/hrt.69.5.377","article-title":"Risk of thrombosis in human atherosclerotic plaques: role of extracellular lipid, macrophage, and smooth muscle cell content","volume":"69","author":"Davies","year":"1993","journal-title":"Br Heart J"},{"key":"R11-12-20210204","doi-asserted-by":"crossref","first-page":"586","DOI":"10.3181\/00379727-95-23300","article-title":"Resolution of aortic atherosclerotic infiltration in the rabbit by phosphatide infusion","volume":"95","author":"Friedman","year":"1957","journal-title":"Proc Soc Exp Biol Med"},{"key":"R12-12-20210204","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1353\/pbm.1984.0031","article-title":"Intravenously administered lecithin liposomes: a synthetic antiatherogenic lipid particle","volume":"27","author":"Williams","year":"1984","journal-title":"Perspect Biol Med"},{"key":"R13-12-20210204","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1161\/01.ATV.0000174795.62387.d3","article-title":"Lipoprotein retention \u2013 and clues for atheroma regression","volume":"25","author":"Williams","year":"2005","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R14-12-20210204","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/0005-2760(86)90167-0","article-title":"Uptake of endogenous cholesterol by a synthetic lipoprotein","volume":"875","author":"Williams","year":"1986","journal-title":"Biochim Biophys Acta"},{"key":"R15-12-20210204","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1073\/pnas.85.1.242","article-title":"Low density lipoprotein receptor-independent hepatic uptake of a synthetic, cholesterol-scavenging lipoprotein: implications for the treatment of receptor-deficient atherosclerosis","volume":"85","author":"Williams","year":"1988","journal-title":"Proc Natl Acad Sci USA"},{"key":"R16-12-20210204","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1161\/01.ATV.17.10.2132","article-title":"Large versus small unilamellar vesicles mediate reverse cholesterol transport in vivo into two distinct hepatic metabolic pools. Implications for the treatment of atherosclerosis","volume":"17","author":"Rodrigueza","year":"1997","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R17-12-20210204","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1161\/01.ATV.20.4.1033","article-title":"Rapid restoration of normal endothelial functions in genetically hyperlipidemic mice by a synthetic mediator of reverse lipid transport","volume":"20","author":"Williams","year":"2000","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R18-12-20210204","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1161\/01.ATV.17.2.383","article-title":"Remodeling and shuttling. Mechanisms for the synergistic effects between different acceptor particles in the mobilization of cellular cholesterol","volume":"17","author":"Rodrigueza","year":"1997","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R19-12-20210204","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0169-409X(97)00130-0","article-title":"Structural and metabolic consequences of liposome-lipoprotein interactions","volume":"32","author":"Williams","year":"1998","journal-title":"Adv Drug Deliv Rev"},{"key":"R20-12-20210204","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S0368-1319(68)80060-2","article-title":"Nutritional control of coronary artery atherosclerosis in the squirrel monkey","volume":"8","author":"Maruffo","year":"1968","journal-title":"J Atheroscler Res"},{"key":"R21-12-20210204","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1161\/01.RES.27.1.59","article-title":"Regression of coronary atheromatosis in rhesus monkeys","volume":"27","author":"Armstrong","year":"1970","journal-title":"Circ Res"},{"key":"R22-12-20210204","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1136\/pgmj.52.609.456","article-title":"Evidence of regression of atherosclerosis in primates and man","volume":"52","author":"Armstrong","year":"1976","journal-title":"Postgrad Med J"},{"key":"R23-12-20210204","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/0021-9150(83)90097-7","article-title":"Experimental models of atherosclerosis regression","volume":"48","author":"Malinow","year":"1983","journal-title":"Atherosclerosis"},{"key":"R24-12-20210204","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1172\/JCI114558","article-title":"Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit","volume":"85","author":"Badimon","year":"1990","journal-title":"J Clin Invest"},{"key":"R25-12-20210204","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1161\/01.ATV.15.11.1882","article-title":"Intravenous injection of rabbit apolipoprotein A-I inhibits the progression of atherosclerosis in cholesterol-fed rabbits","volume":"15","author":"Miyazaki","year":"1995","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R26-12-20210204","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/0092-8674(92)90362-G","article-title":"Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells","volume":"71","author":"Plump","year":"1992","journal-title":"Cell"},{"key":"R27-12-20210204","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1126\/science.1411543","article-title":"Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E","volume":"258","author":"Zhang","year":"1992","journal-title":"Science"},{"key":"R28-12-20210204","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1172\/JCI116663","article-title":"Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery","volume":"92","author":"Ishibashi","year":"1993","journal-title":"J Clin Invest"},{"key":"R29-12-20210204","doi-asserted-by":"crossref","first-page":"3047","DOI":"10.1161\/hc2501.092494","article-title":"High-dose recombinant apolipoprotein A-I(milano) mobilizes tissue cholesterol and rapidly reduces plaque lipid and macrophage content in apolipoprotein e-deficient mice. Potential implications for acute plaque stabilization","volume":"103","author":"Shah","year":"2001","journal-title":"Circulation"},{"key":"R30-12-20210204","doi-asserted-by":"crossref","first-page":"11779","DOI":"10.1073\/pnas.0403259101","article-title":"Emigration of monocyte-derived cells from atherosclerotic lesions characterizes regressive, but not progressive, plaques","volume":"101","author":"Llodra","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"key":"R31-12-20210204","doi-asserted-by":"crossref","first-page":"3781","DOI":"10.1073\/pnas.0511043103","article-title":"Gene expression changes in foam cells and the role of chemokine receptor CCR7 during atherosclerosis regression in ApoE-deficient mice","volume":"103","author":"Trogan","year":"2006","journal-title":"Proc Natl Acad Sci USA"},{"key":"R32-12-20210204","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1067\/mva.2001.115963","article-title":"Dramatic remodeling of advanced atherosclerotic plaques of the apolipoprotein E-deficient mouse in a novel transplantation model","volume":"34","author":"Reis","year":"2001","journal-title":"J Vasc Surg"},{"key":"R33-12-20210204","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1161\/01.ATV.0000139313.69015.1c","article-title":"Serial studies of mouse atherosclerosis by in vivo magnetic resonance imaging detect lesion regression after correction of dyslipidemia","volume":"24","author":"Trogan","year":"2004","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R34-12-20210204","doi-asserted-by":"crossref","first-page":"166","DOI":"10.3121\/cmr.3.3.166","article-title":"Immunoregulation of dendritic cells","volume":"3","author":"Wallet","year":"2005","journal-title":"Clin Med Res"},{"key":"R35-12-20210204","doi-asserted-by":"crossref","first-page":"2234","DOI":"10.1073\/pnas.042683999","article-title":"Laser capture microdissection analysis of gene expression in macrophages from atherosclerotic lesions of apolipoprotein E-deficient mice","volume":"99","author":"Trogan","year":"2002","journal-title":"Proc Natl Acad Sci USA"},{"key":"R36-12-20210204","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/978-1-60327-369-5_5","article-title":"Laser capture microdissection for analysis of macrophage gene expression from atherosclerotic lesions","volume":"1027","author":"Feig","year":"2013","journal-title":"Methods Mol Biol"},{"key":"R37-12-20210204","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0092-8674(00)80059-8","article-title":"CCR7 coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs","volume":"99","author":"Forster","year":"1999","journal-title":"Cell"},{"key":"R38-12-20210204","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/0002-9343(77)90874-9","article-title":"High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study","volume":"62","author":"Gordon","year":"1977","journal-title":"Am J Med"},{"key":"R39-12-20210204","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1001\/jama.1986.03380200073024","article-title":"Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study","volume":"256","author":"Castelli","year":"1986","journal-title":"JAMA"},{"key":"R40-12-20210204","doi-asserted-by":"crossref","first-page":"9N","DOI":"10.1016\/S0002-9149(01)02146-4","article-title":"Epidemiologic evidence for high-density lipoprotein cholesterol as a risk factor for coronary artery disease","volume":"88","author":"Franceschini","year":"2001","journal-title":"Am J Cardiol"},{"key":"R41-12-20210204","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1056\/NEJM198911093211907","article-title":"High-density lipoprotein \u2013 the clinical implications of recent studies","volume":"321","author":"Gordon","year":"1989","journal-title":"N Engl J Med"},{"key":"R42-12-20210204","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0140-6736(75)91977-7","article-title":"Letter: high-density lipoprotein and atherosclerosis","volume":"1","author":"Miller","year":"1975","journal-title":"Lancet"},{"key":"R43-12-20210204","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/00041433-199606000-00005","article-title":"High density lipoprotein and lipoprotein oxidation","volume":"7","author":"Banka","year":"1996","journal-title":"Curr Opin Lipidol"},{"key":"R44-12-20210204","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0022-2275(20)39898-9","article-title":"Molecular physiology of reverse cholesterol transport","volume":"36","author":"Fielding","year":"1995","journal-title":"J Lipid Res"},{"key":"R45-12-20210204","doi-asserted-by":"crossref","first-page":"196","DOI":"10.2174\/138945008783755557","article-title":"Atheroprotective effects of HDL: beyond reverse cholesterol transport","volume":"9","author":"Feig","year":"2008","journal-title":"Curr Drug Targets"},{"key":"R46-12-20210204","doi-asserted-by":"crossref","first-page":"III8","DOI":"10.1161\/01.CIR.0000131512.50667.46","article-title":"HDL cholesterol and protective factors in atherosclerosis","volume":"109","author":"Assmann","year":"2004","journal-title":"Circulation"},{"key":"R47-12-20210204","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.tcm.2005.08.005","article-title":"Atheroprotective effects of high-density lipoprotein-associated lysosphingolipids","volume":"15","author":"Nofer","year":"2005","journal-title":"Trends Cardiovasc Med"},{"key":"R48-12-20210204","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0021-9150(01)00651-7","article-title":"HDL and arteriosclerosis: beyond reverse cholesterol transport","volume":"161","author":"Nofer","year":"2002","journal-title":"Atherosclerosis"},{"key":"R49-12-20210204","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/353265a0","article-title":"Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI","volume":"353","author":"Rubin","year":"1991","journal-title":"Nature"},{"key":"R50-12-20210204","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1172\/JCI117412","article-title":"Apolipoprotein AI transgene corrects apolipoprotein E deficiency-induced atherosclerosis in mice","volume":"94","author":"Paszty","year":"1994","journal-title":"J Clin Invest"},{"key":"R51-12-20210204","doi-asserted-by":"crossref","first-page":"9607","DOI":"10.1073\/pnas.91.20.9607","article-title":"Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse","volume":"91","author":"Plump","year":"1994","journal-title":"Proc Natl Acad Sci USA"},{"key":"R52-12-20210204","doi-asserted-by":"crossref","first-page":"9774","DOI":"10.1073\/pnas.0403506101","article-title":"ATP-binding cassette transporters G1 and G4 mediate cellular cholesterol efflux to high-density lipoproteins","volume":"101","author":"Wang","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"key":"R53-12-20210204","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1161\/01.ATV.0000218998.75963.02","article-title":"LXR-induced redistribution of ABCG1 to plasma membrane in macrophages enhances cholesterol mass efflux to HDL","volume":"26","author":"Wang","year":"2006","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R54-12-20210204","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.1172\/JCI32057","article-title":"Macrophage ABCA1 and ABCG1, but not SR-BI, promote macrophage reverse cholesterol transport in vivo","volume":"117","author":"Wang","year":"2007","journal-title":"J Clin Invest"},{"key":"R55-12-20210204","first-page":"3900","article-title":"Combined deficiency of ABCA1 and ABCG1 promotes foam cell accumulation and accelerates atherosclerosis in mice","volume":"117","author":"Yvan-Charvet","year":"2007","journal-title":"J Clin Invest"},{"key":"R56-12-20210204","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1161\/CIRCULATIONAHA.108.793869","article-title":"Increased inflammatory gene expression in ABC transporter-deficient macrophages: free cholesterol accumulation, increased signaling via toll-like receptors, and neutrophil infiltration of atherosclerotic lesions","volume":"118","author":"Yvan-Charvet","year":"2008","journal-title":"Circulation"},{"key":"R57-12-20210204","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1161\/01.CIR.92.5.1355","article-title":"A definition of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association","volume":"92","author":"Stary","year":"1995","journal-title":"Circulation"},{"key":"R58-12-20210204","doi-asserted-by":"crossref","first-page":"11278","DOI":"10.1074\/jbc.275.15.11278","article-title":"High density lipoprotein prevents oxidized low density lipoprotein-induced inhibition of endothelial nitric-oxide synthase localization and activation in caveolae","volume":"275","author":"Uittenbogaard","year":"2000","journal-title":"J Biol Chem"},{"key":"R59-12-20210204","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1161\/01.CIR.101.11.1261","article-title":"Effect of native and oxidized low-density lipoprotein on endothelial nitric oxide and superoxide production: key role of L-arginine availability","volume":"101","author":"Vergnani","year":"2000","journal-title":"Circulation"},{"key":"R60-12-20210204","doi-asserted-by":"crossref","first-page":"11058","DOI":"10.1074\/jbc.M110985200","article-title":"High density lipoprotein binding to scavenger receptor, class B, type I activates endothelial nitric-oxide synthase in a ceramide-dependent manner","volume":"277","author":"Li","year":"2002","journal-title":"J Biol Chem"},{"key":"R61-12-20210204","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1038\/89986","article-title":"High-density lipoprotein binding to scavenger receptor-BI activates endothelial nitric oxide synthase","volume":"7","author":"Yuhanna","year":"2001","journal-title":"Nat Med"},{"key":"R62-12-20210204","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1161\/01.RES.0000225982.01988.93","article-title":"Endothelial and antithrombotic actions of HDL","volume":"98","author":"Mineo","year":"2006","journal-title":"Circ Res"},{"key":"R63-12-20210204","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1161\/01.RES.0000199272.59432.5b","article-title":"High-density lipoprotein promotes endothelial cell migration and reendothelialization via scavenger receptor-B type I","volume":"98","author":"Seetharam","year":"2006","journal-title":"Circ Res"},{"key":"R64-12-20210204","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1096\/fj.99-1029com","article-title":"HDL-associated PAF-AH reduces endothelial adhesiveness in apoE-\/- mice","volume":"14","author":"Theilmeier","year":"2000","journal-title":"FASEB J"},{"key":"R65-12-20210204","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1161\/01.ATV.21.4.481","article-title":"HDL and the inflammatory response induced by LDL-derived oxidized phospholipids","volume":"21","author":"Navab","year":"2001","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R66-12-20210204","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1016\/S0022-2275(20)33462-3","article-title":"Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: steps 2 and 3","volume":"41","author":"Navab","year":"2000","journal-title":"J Lipid Res"},{"key":"R67-12-20210204","doi-asserted-by":"crossref","first-page":"24473","DOI":"10.1074\/jbc.M010459200","article-title":"Apolipoprotein A-I promotes the formation of phosphatidylcholine core aldehydes that are hydrolyzed by paraoxonase (PON-1) during high density lipoprotein oxidation with a peroxynitrite donor","volume":"276","author":"Ahmed","year":"2001","journal-title":"J Biol Chem"},{"key":"R68-12-20210204","doi-asserted-by":"crossref","first-page":"10316","DOI":"10.1073\/pnas.89.21.10316","article-title":"High density lipoprotein is the major carrier of lipid hydroperoxides in human blood plasma from fasting donors","volume":"89","author":"Bowry","year":"1992","journal-title":"Proc Natl Acad Sci USA"},{"key":"R69-12-20210204","doi-asserted-by":"crossref","first-page":"6080","DOI":"10.1074\/jbc.273.11.6080","article-title":"Oxidation of high density lipoproteins. I. Formation of methionine sulfoxide in apolipoproteins AI and AII is an early event that accompanies lipid peroxidation and can be enhanced by alpha-tocopherol","volume":"273","author":"Garner","year":"1998","journal-title":"J Biol Chem"},{"key":"R70-12-20210204","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1161\/hc4501.098952","article-title":"Elevating high-density lipoprotein cholesterol in apolipoprotein E-deficient mice remodels advanced atherosclerotic lesions by decreasing macrophage and increasing smooth muscle cell content","volume":"104","author":"Rong","year":"2001","journal-title":"Circulation"},{"key":"R71-12-20210204","doi-asserted-by":"crossref","first-page":"7166","DOI":"10.1073\/pnas.1016086108","article-title":"HDL promotes rapid atherosclerosis regression in mice and alters inflammatory properties of plaque monocyte-derived cells","volume":"108","author":"Feig","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"key":"R72-12-20210204","first-page":"e13","article-title":"ApoAI is required for the regression of atherosclerosis and is a potent regulator of plaque monocyte-derived emigration and inflammatory state","volume":"29","author":"Feig","year":"2009","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R73-12-20210204","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1001\/jama.297.5.499","article-title":"Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis","volume":"297","author":"Nicholls","year":"2007","journal-title":"JAMA"},{"key":"R74-12-20210204","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1161\/01.ATV.0000255581.38523.7c","article-title":"Enhanced expression of the homeostatic chemokines CCL19 and CCL21 in clinical and experimental atherosclerosis: possible pathogenic role in plaque destabilization","volume":"27","author":"Damas","year":"2007","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R75-12-20210204","doi-asserted-by":"crossref","first-page":"e28534","DOI":"10.1371\/journal.pone.0028534","article-title":"Statins promote the regression of atherosclerosis via activation of the CCR7-dependent emigration pathway in macrophages","volume":"6","author":"Feig","year":"2011","journal-title":"PLoS One"},{"key":"R76-12-20210204","doi-asserted-by":"crossref","first-page":"22930","DOI":"10.1074\/jbc.M801408200","article-title":"Increased cellular free cholesterol in macrophage-specific Abca1 knock-out mice enhances pro-inflammatory response of macrophages","volume":"283","author":"Zhu","year":"2008","journal-title":"J Biol Chem"},{"key":"R77-12-20210204","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1161\/CIRCULATIONAHA.110.984146","article-title":"Reversal of hyperlipidemia with a genetic switch favorably affects the content and inflammatory state of macrophages in atherosclerotic plaques","volume":"123","author":"Feig","year":"2011","journal-title":"Circulation"},{"key":"R78-12-20210204","doi-asserted-by":"crossref","first-page":"e39790","DOI":"10.1371\/journal.pone.0039790","article-title":"Regression of atherosclerosis is characterized by broad changes in the plaque macrophage transcriptome","volume":"7","author":"Feig","year":"2012","journal-title":"PLoS One"},{"key":"R79-12-20210204","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1172\/JCI57275","article-title":"Antagonism of miR-33 in mice promotes reverse cholesterol transport and regression of atherosclerosis","volume":"121","author":"Rayner","year":"2011","journal-title":"J Clin Invest"},{"key":"R80-12-20210204","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1038\/nature10486","article-title":"Inhibition of miR-33a\/b in non-human primates raises plasma HDL and lowers VLDL triglycerides","volume":"478","author":"Rayner","year":"2011","journal-title":"Nature"},{"key":"R81-12-20210204","first-page":"241","article-title":"Regression of peripheral atherosclerosis during therapy with high doses of nicotinic acid","volume":"99","author":"Ost","year":"1967","journal-title":"Scand J Clin Lab Invest Suppl"},{"key":"R82-12-20210204","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1161\/01.CIR.87.6.1781","article-title":"Lipid lowering and plaque regression. New insights into prevention of plaque disruption and clinical events in coronary disease","volume":"87","author":"Brown","year":"1993","journal-title":"Circulation"},{"key":"R83-12-20210204","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1146\/annurev.me.44.020193.002053","article-title":"Atherosclerosis regression, plaque disruption, and cardiovascular events: a rationale for lipid lowering in coronary artery disease","volume":"44","author":"Brown","year":"1993","journal-title":"Annu Rev Med"},{"key":"R84-12-20210204","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1053\/pcad.2002.123474","article-title":"Dyslipidemia and the vulnerable plaque","volume":"44","author":"Farmer","year":"2002","journal-title":"Prog Cardiovasc Dis"},{"key":"R85-12-20210204","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1056\/NEJM199812313392703","article-title":"Effect of HMG-CoA reductase inhibitors on coronary artery disease as assessed by electron-beam computed tomography","volume":"339","author":"Callister","year":"1998","journal-title":"N Engl J Med"},{"key":"R86-12-20210204","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1001\/jama.291.9.1071","article-title":"Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial","volume":"291","author":"Nissen","year":"2004","journal-title":"JAMA"},{"key":"R87-12-20210204","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1001\/jama.295.13.jpc60002","article-title":"Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial","volume":"295","author":"Nissen","year":"2006","journal-title":"JAMA"},{"key":"R88-12-20210204","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1016\/j.jacc.2005.04.064","article-title":"Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: a PROVE IT-TIMI 22 substudy","volume":"46","author":"Wiviott","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"R89-12-20210204","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1001\/jama.290.17.2292","article-title":"Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial","volume":"290","author":"Nissen","year":"2003","journal-title":"JAMA"},{"key":"R90-12-20210204","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1001\/jama.297.15.jpc70004","article-title":"Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial","volume":"297","author":"Tardif","year":"2007","journal-title":"JAMA"},{"key":"R91-12-20210204","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1161\/CIRCRESAHA.108.182063","article-title":"Infusion of reconstituted high-density lipoprotein leads to acute changes in human atherosclerotic plaque","volume":"103","author":"Shaw","year":"2008","journal-title":"Circ Res"},{"key":"R92-12-20210204","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1001\/jama.285.12.1585","article-title":"Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial","volume":"285","author":"Robins","year":"2001","journal-title":"JAMA"},{"key":"R93-12-20210204","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1161\/01.CIR.0000034508.55617.65","article-title":"ARBITER: Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol: a randomized trial comparing the effects of atorvastatin and pravastatin on carotid intima medial thickness","volume":"106","author":"Taylor","year":"2002","journal-title":"Circulation"},{"key":"R94-12-20210204","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1185\/030079906X148508","article-title":"The effect of 24 months of combination statin and extended-release niacin on carotid intima-media thickness: ARBITER 3","volume":"22","author":"Taylor","year":"2006","journal-title":"Curr Med Res Opin"},{"key":"R95-12-20210204","doi-asserted-by":"crossref","first-page":"3512","DOI":"10.1161\/01.CIR.0000148955.19792.8D","article-title":"Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins","volume":"110","author":"Taylor","year":"2004","journal-title":"Circulation"},{"key":"R96-12-20210204","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1056\/NEJMoa0907569","article-title":"Extended-release niacin or ezetimibe and carotid intima-media thickness","volume":"361","author":"Taylor","year":"2009","journal-title":"N Engl J Med"},{"key":"R97-12-20210204","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.mehy.2006.11.026","article-title":"Anti-inflammatory effect is an important property of niacin on atherosclerosis beyond its lipid-altering effects","volume":"69","author":"Yu","year":"2007","journal-title":"Med Hypotheses"},{"key":"R98-12-20210204","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/S0002-9149(01)01639-3","article-title":"Effect of niacin and atorvastatin on lipoprotein subclasses in patients with atherogenic dyslipidemia","volume":"88","author":"McKenney","year":"2001","journal-title":"Am J Cardiol"},{"key":"R99-12-20210204","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/0021-9150(92)90177-I","article-title":"Differential effects of nicotinic acid in subjects with different LDL subclass patterns","volume":"95","author":"Superko","year":"1992","journal-title":"Atherosclerosis"},{"key":"R100-12-20210204","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1056\/NEJMoa011090","article-title":"Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease","volume":"345","author":"Brown","year":"2001","journal-title":"N Engl J Med"},{"key":"R101-12-20210204","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMoa1107579","article-title":"Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy","volume":"365","author":"Boden","year":"2011","journal-title":"N Engl J Med"},{"key":"R102-12-20210204","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa1300955","article-title":"Effects of extended-release niacin with laropiprant in high-risk patients","volume":"371","author":"Landray","year":"2014","journal-title":"N Engl J Med"},{"key":"R103-12-20210204","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1056\/NEJMoa0706628","article-title":"Effects of torcetrapib in patients at high risk for coronary events","volume":"357","author":"Barter","year":"2007","journal-title":"N Engl J Med"},{"key":"R104-12-20210204","doi-asserted-by":"crossref","first-page":"10E","DOI":"10.1016\/j.amjcard.2009.09.014","article-title":"Lessons learned from the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial","volume":"104","author":"Barter","year":"2009","journal-title":"Am J Cardiol"},{"key":"R105-12-20210204","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1161\/CIRCULATIONAHA.108.790733","article-title":"Cholesteryl ester transfer protein inhibition, high-density lipoprotein raising, and progression of coronary atherosclerosis: insights from ILLUSTRATE (Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of Atherosclerosis by CETP Inhibition and HDL Elevation)","volume":"118","author":"Nicholls","year":"2008","journal-title":"Circulation"},{"key":"R106-12-20210204","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1161\/ATVBAHA.110.207142","article-title":"Cholesterol efflux potential and antiinflammatory properties of high-density lipoprotein after treatment with niacin or anacetrapib","volume":"30","author":"Yvan-Charvet","year":"2010","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R107-12-20210204","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1161\/ATVBAHA.106.138347","article-title":"Inhibition of cholesteryl ester transfer protein by torcetrapib modestly increases macrophage cholesterol efflux to HDL","volume":"27","author":"Yvan-Charvet","year":"2007","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R108-12-20210204","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1093\/eurheartj\/ehs019","article-title":"Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: the dal-VESSEL randomized clinical trial","volume":"33","author":"Luscher","year":"2012","journal-title":"Eur Heart J"},{"key":"R109-12-20210204","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.ahj.2009.07.028","article-title":"Design of the DEFINE trial: determining the EFficacy and tolerability of CETP INhibition with AnacEtrapib","volume":"158","author":"Cannon","year":"2009","journal-title":"Am Heart J"},{"key":"R110-12-20210204","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1056\/NEJMoa1009744","article-title":"Safety of anacetrapib in patients with or at high risk for coronary heart disease","volume":"363","author":"Cannon","year":"2010","journal-title":"N Engl J Med"},{"key":"R111-12-20210204","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1001\/jama.2011.1649","article-title":"Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial","volume":"306","author":"Nicholls","year":"2011","journal-title":"JAMA"},{"key":"R112-12-20210204","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1097\/MOL.0b013e328353ef1d","article-title":"Rationale for cholesteryl ester transfer protein inhibition","volume":"23","author":"Hewing","year":"2012","journal-title":"Curr Opin Lipidol"},{"key":"R113-12-20210204","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/S0140-6736(12)60312-2","article-title":"Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study","volume":"380","author":"Voight","year":"2012","journal-title":"Lancet"},{"key":"R114-12-20210204","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa1206797","article-title":"Effects of dalcetrapib in patients with a recent acute coronary syndrome","volume":"367","author":"Schwartz","year":"2012","journal-title":"N Engl J Med"},{"key":"R115-12-20210204","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.ahj.2009.09.017","article-title":"Rationale and design of the dal-OUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome","volume":"158","author":"Schwartz","year":"2009","journal-title":"Am Heart J"},{"key":"R116-12-20210204","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1056\/NEJMoa1001689","article-title":"Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis","volume":"364","author":"Khera","year":"2011","journal-title":"N Engl J Med"},{"key":"R117-12-20210204","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1056\/NEJMoa1409065","article-title":"HDL cholesterol efflux capacity and incident cardiovascular events","volume":"371","author":"Rohatgi","year":"2014","journal-title":"N Engl J Med"},{"key":"R118-12-20210204","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1093\/eurheartj\/ehu105","article-title":"The effect of cholesteryl ester transfer protein inhibition on lipids, lipoproteins, and markers of HDL function after an acute coronary syndrome: the dal-ACUTE randomized trial","volume":"35","author":"Ray","year":"2014","journal-title":"Eur Heart J"},{"key":"R119-12-20210204","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1161\/CIRCULATIONAHA.105.565135","article-title":"Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial","volume":"113","author":"Otvos","year":"2006","journal-title":"Circulation"},{"key":"R120-12-20210204","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.jacc.2012.03.060","article-title":"High-density lipoprotein cholesterol and particle concentrations, carotid atherosclerosis, and coronary events: MESA (multi-ethnic study of atherosclerosis)","volume":"60","author":"Mackey","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"R121-12-20210204","doi-asserted-by":"crossref","first-page":"e000037","DOI":"10.1161\/JAHA.113.000037","article-title":"Changes in lipoprotein particle number with ezetimibe\/simvastatin coadministered with extended-release niacin in hyperlipidemic patients","volume":"2","author":"Le","year":"2013","journal-title":"J Am Heart Assoc"},{"key":"R122-12-20210204","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1161\/CIRCULATIONAHA.113.002671","article-title":"High-density lipoprotein cholesterol, size, particle number, and residual vascular risk after potent statin therapy","volume":"128","author":"Mora","year":"2013","journal-title":"Circulation"},{"key":"R123-12-20210204","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1161\/CIRCRESAHA.114.300760","article-title":"High-density lipoprotein and atherosclerosis regression: evidence from preclinical and clinical studies","volume":"114","author":"Feig","year":"2014","journal-title":"Circ Res"},{"key":"R124-12-20210204","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1161\/ATVBAHA.114.303720","article-title":"CSL112 enhances biomarkers of reverse cholesterol transport after single and multiple infusions in healthy subjects","volume":"34","author":"Gille","year":"2014","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R125-12-20210204","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/nrcardio.2010.200","article-title":"Novel HDL-directed pharmacotherapeutic strategies","volume":"8","author":"Degoma","year":"2011","journal-title":"Nat Rev Cardiol"},{"key":"R126-12-20210204","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1194\/jlr.M800374-JLR200","article-title":"LXR agonist suppresses atherosclerotic lesion growth and promotes lesion regression in ApoE*3Leiden mice: time course and potential mechanisms","volume":"50","author":"Verschuren","year":"2009","journal-title":"J Lipid Res"},{"key":"R127-12-20210204","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.aogh.2013.12.001","article-title":"Regression of atherosclerosis: insights from animal and clinical studies","volume":"80","author":"Feig","year":"2014","journal-title":"Ann Glob Health"},{"key":"R128-12-20210204","doi-asserted-by":"crossref","first-page":"286","DOI":"10.3389\/fphys.2012.00286","article-title":"Macrophages, dendritic cells, and regression of atherosclerosis","volume":"3","author":"Feig","year":"2012","journal-title":"Front Physiol"},{"key":"R129-12-20210204","doi-asserted-by":"crossref","first-page":"4415","DOI":"10.1172\/JCI38911","article-title":"LXR promotes the maximal egress of monocyte-derived cells from mouse aortic plaques during atherosclerosis regression","volume":"120","author":"Feig","year":"2010","journal-title":"J Clin Invest"},{"key":"R130-12-20210204","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1016\/j.bcp.2013.09.019","article-title":"Elimination of macrophages drives LXR-induced regression both in initial and advanced stages of atherosclerotic lesion development","volume":"86","author":"van der Stoep","year":"2013","journal-title":"Biochem Pharmacol"},{"key":"R131-12-20210204","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s11883-015-0499-4","article-title":"Targeting PCSK9 for therapeutic gains","volume":"17","author":"Shapiro","year":"2015","journal-title":"Curr Atheroscler Rep"},{"key":"R132-12-20210204","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1097\/MED.0000000000000137","article-title":"PCSK9 inhibition to reduce cardiovascular disease risk: recent findings from the biology of PCSK9","volume":"22","author":"Tavori","year":"2015","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"R133-12-20210204","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/j.jacc.2007.12.010","article-title":"Dose-related effects of repeated ETC-216 (recombinant apolipoprotein A-I Milano\/1-palmitoyl-2-oleoyl phosphatidylcholine complexes) administrations on rabbit lipid-rich soft plaques: in vivo assessment by intravascular ultrasound and magnetic resonance imaging","volume":"51","author":"Parolini","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"R134-12-20210204","doi-asserted-by":"crossref","first-page":"217","DOI":"10.5551\/jat.509","article-title":"A reconstituted high density lipoprotein containing the V156E mutant of apolipoprotein A-I exhibits anti-atherosclerotic activity in Apo-E deficient mice","volume":"16","author":"Cho","year":"2009","journal-title":"J Atheroscler Thromb"}],"container-title":["Coronary Artery Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MCA.0000000000000408","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T22:40:55Z","timestamp":1620945655000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00019501-201611000-00012"}},"subtitle":["basic mechanisms and clinical implications"],"short-title":[],"issued":{"date-parts":[[2016,11]]},"references-count":134,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1097\/mca.0000000000000408","relation":{},"ISSN":["0954-6928"],"issn-type":[{"value":"0954-6928","type":"print"}],"subject":[],"published":{"date-parts":[[2016,11]]}}}